{"filings":[{"id":834357,"accession_number":"0001628280-26-040342","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2026-06-03T20:25:12+00:00","items":["5.07"],"status":"ready","headline":"Strata Critical Medical stockholders elect directors Heyburn and Lauck, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["William A. Heyburn re-elected with 46,050,902 for, 505,421 withhold, 12,687,496 broker non-votes.","Andrew Lauck re-elected with 39,525,159 for, 7,031,164 withhold, 12,687,496 broker non-votes.","Ratification of Deloitte & Touche as auditor: 58,946,832 for, 65,815 against, 231,172 abstain.","Advisory say-on-pay approved: 38,497,962 for, 8,022,682 against, 35,679 abstain, 12,687,496 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95368,"accession_number":"0001628280-26-030898","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Strata Critical Medical Q1 revenue up 87% to $67.4M; net income $2.4M vs prior loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $67.4M (up 87.4% YoY); net income from cont. ops $2.4M vs loss of $1.6M YoY.","Adjusted EBITDA $6.4M; gross margin improved to 21.0% from 19.6%.","Logistics revenue up 32.4% to $47.6M; Clinical segment contributed $19.8M (new).","Completed bolt-on acquisition of Ohio Valley Perfusion Associates; reiterating full-year 2026 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":67384000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108402,"accession_number":"0001628280-26-013553","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Strata Critical Medical Q4 revenue up 83.5% YoY to $66.8M; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $66.8M (+83.5% YoY); logistics revenue up 35.3% to $49.2M.","Full year 2025 revenue $197.1M, Adjusted EBITDA $14.1M, both above guidance high end.","Full year 2025 net loss from continuing ops $20.1M vs $16.1M in 2024.","FY2026 revenue guidance raised to $260-275M; Adjusted EBITDA guidance raised to $29-33M.","Clinical segment (Keystone) contributed $17.6M revenue in Q4; total gross profit $14.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108401,"accession_number":"0001104659-26-010689","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Strata Critical Medical secures $30M ABL credit facility from JPMorgan for acquisitions","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Credit Agreement for up to $30M revolving ABL facility, expandable to $50M subject to conditions.","Facility is undrawn at close; proceeds to be used for working capital and future tuck-in acquisitions.","Owned aircraft excluded from collateral, preserving future financing optionality.","Maturity date January 30, 2029; interest at SOFR plus 2.00% margin.","Springing financial covenant: minimum Fixed Charge Coverage Ratio of 1.05x when availability < greater of $5M or 20% of commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124841,"accession_number":"0001104659-25-118180","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Strata Critical Medical appoints Will Cook to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William L. Cook III appointed as Class I director effective Dec 2, 2025; board expanded from eight to nine directors.","Cook is President & CEO of Vail Health; joins Compensation and Nominating & Governance Committees.","Granted 33,157 RSUs vesting at 2027 annual meeting; standard non-employee director compensation pro-rated.","No family relationships or reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124839,"accession_number":"0001628280-25-054709","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K/A","filed_at":"2025-12-02T23:59:59+00:00","items":["9.01","2.01"],"status":"ready","headline":"Strata Critical Medical amends 8-K to include Keystone financials; acquisition closed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Keystone Perfusion Services closed Sep 16, 2025; all equity interests acquired.","Keystone's audited FY2024: revenue $42.9M, net income $2.97M, total assets $16.9M.","Amendment adds historical audited and unaudited financials of Keystone and pro forma combined statements.","Sale of Passenger business to Joby Aero also referenced as part of overall transactions.","Pro forma financials for FY2024, FY2023, and nine months ended Sep 30, 2025 filed as Exhibit 99.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124840,"accession_number":"0001628280-25-050785","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Strata Critical Medical Q3 revenue up 36.7% to $49.3M; net loss widens to $9.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $49.3M, up 36.7% YoY; organic growth 29.0% excluding Keystone acquisition.","Net loss from continuing ops $(9.7)M, widened from $(5.6)M in prior-year period.","Medical Segment Adjusted EBITDA $7.6M, +93.5% YoY; margin 15.3% (up 450 bps).","Raised FY2025 revenue guidance to $185-195M; reaffirmed Adjusted EBITDA range.","Investor Day on Nov 17, 2025 to introduce FY2026 guidance and medium-term targets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":130354000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141545,"accession_number":"0001779128-25-000114","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","2.01","9.01","3.02","7.01"],"status":"ready","headline":"Strata completes $124M acquisition of Keystone Perfusion, updates 2025 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total upfront consideration of $124M (88% cash, 12% stock) at ~9x Keystone's estimated 2025 Adjusted EBITDA of ~$13M.","Up to $23M earn-out payable upon achieving ~25% gross profit growth in each of 2026, 2027, and 2028.","Keystone expected to generate ~$65M revenue and ~$13M Adjusted EBITDA in 2025, with >50% YoY revenue growth.","Updated full-year 2025 guidance: revenue $180-190M, Adjusted EBITDA $13-14M (includes Keystone from Sep 16).","Founder/CEO Louis Verdetto, Michael Hancock, and Christie Campbell remain in current roles post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141543,"accession_number":"0001779128-25-000102","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K/A","filed_at":"2025-09-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Strata Critical Medical Board sets annual say-on-pay votes until 2031","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted for annual say-on-pay frequency at May 6, 2025 meeting.","Compensation Committee determined to hold annual say-on-pay votes until next frequency vote no later than 2031.","Board may reconsider frequency before 2031 if it chooses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141544,"accession_number":"0001104659-25-085185","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","2.01","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Strata Critical Medical closes Passenger sale to Joby for ~$76M in stock; shifts to medical transport","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed sale of Passenger business to Joby Aero on Aug 29; received ~$76M in 5.3M Joby shares, plus up to $35M earnout and $10M holdbacks.","Name changed to Strata Critical Medical; Nasdaq tickers become SRTA (common) and SRTAW (warrants).","Melissa Tomkiel and William Heyburn appointed co-CEOs; both join Board; directors Borthwick and Lerer resigned.","Pro forma shows continuing ops net loss of $1.45M for H1 2025 vs $7.24M reported, reflecting Passenger divestiture.","Company issued updated FY2025 financial guidance; see press release Exhibit 99.2 for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141542,"accession_number":"0001104659-25-085182","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K/A","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Strata Critical Medical appoints Co-CEOs Tomkiel and Heyburn, approves $550K salary and PSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melissa Tomkiel and William Heyburn became Co-CEOs effective Aug 1, 2025, retaining General Counsel and CFO roles respectively.","Base salary for each Co-CEO increased to $550,000, approved by the Board on Aug 27, 2025.","Each received PSUs with target values: $500,000 based on Passenger business 12-month targets, and $2,000,000 on three-year company performance.","On termination without cause or for good reason, unvested time-vesting equity vests up to 18 months; performance-vesting PSUs vest pro-rata with 548-day add-on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141541,"accession_number":"0001779128-25-000058","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Air Mobility Q2 net loss narrows to $3.7M; sells Passenger division to Joby for up to $125M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 net loss improved $7.6M YoY to $(3.7)M; Adjusted EBITDA $3.2M vs $0.96M YoY.","Medical revenue grew 17.6% YoY; Medical Adjusted EBITDA $6.0M (+9.3%).","Sells Blade Passenger division to Joby Aviation for up to $125M; Medical becomes standalone public company rebranded as Strata.","Sale expected to be Adjusted EBITDA and Free Cash Flow neutral on a go forward basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141540,"accession_number":"0001104659-25-073338","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Blade sells passenger division to Joby for up to $125M; to rebrand as Strata","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Up to $125M consideration (cash or Joby stock): $90M at close plus up to $35M earnout tied to performance and retention.","Blade's medical division remains public and rebrands as Strata, focusing on contractual medical logistics and organ transport.","CEO Rob Wiesenthal joins Joby as CEO of Blade unit, becomes Chairman of Strata; co-CEOs Tomkiel and Heyburn lead Strata.","Transaction expected to be Adjusted EBITDA and FCF neutral; $7M in annual corporate cost efficiencies identified.","Expected close in coming weeks; Blade's Passenger business includes US/Europe operations and the Blade brand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159391,"accession_number":"0001779128-25-000039","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Q1 revenue $54.3M (+5.4% YoY); net loss improves to $(3.5)M; reaffirms FY2025 positive Adj. EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $54.3M (+5.4% YoY); excluding exited Canada, up 10.9%.","Net loss $(3.5)M, improved $0.7M YoY; Adj. EBITDA $(1.2)M, improved $2.3M YoY.","Passenger segment Adj. EBITDA $0.1M, first profitable Q1 since IPO (+$2.7M YoY).","Medical segment Adj. EBITDA $4.1M; new monthly trip volume record set in April 2025.","Reaffirms guidance: double-digit millions of Adjusted EBITDA for full-year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":54306000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159390,"accession_number":"0001779128-25-000037","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Blade Air Mobility annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class I directors elected: John Borthwick (39.3M for, 6.4M withhold), Reginald Love (28.7M for, 17.0M withhold), Edward Philip (43.5M for, 2.2M withhold).","Ratification of Deloitte & Touche as auditor for FY2025 passed with 62.0M for, 62.7K against.","Advisory say-on-frequency vote: 43.7M favored 1-year frequency vs. 1.9M for 3-year.","Advisory say-on-pay approved with 30.0M for, 14.9M against, 680K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177786,"accession_number":"0001779128-25-000007","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Air Mobility Q4 revenue up 14.5% to $54.4M; Net loss narrows 71% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $54.4M (+14.5% YoY); net loss improved 71% to $(9.8)M from $(33.9)M.","Full-year net loss improved to $(27.3)M from $(56.1)M; Adjusted EBITDA $1.2M vs $(16.6)M prior year.","Medical Segment Q4 Adjusted EBITDA rose 119.6% to $5.5M.","Reaffirmed 2025 guidance for double-digit millions of Adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194492,"accession_number":"0001779128-24-000123","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Air Mobility Q3 revenue $74.9M (+4.8%); net loss $(2.0)M; Adj EBITDA $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $74.9M, up 4.8% YoY; gross margin improved 520 bps to 19.3%.","Net loss $(2.0)M vs income $0.3M YoY; Adjusted EBITDA $4.2M, improvement of $3.4M.","Operating cash flow $6.4M, up $4.3M; free cash flow before aircraft acquisitions $3.7M, up $2.4M.","Medical segment Adj EBITDA improved 15.1%; Passenger segment Adj EBITDA up $2.8M, achieving trailing 12-month profitability.","Reaffirmed guidance: positive Adjusted EBITDA in 2024 and double-digit millions in 2025; announced strategic alliance with OrganOx."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":194336000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210822,"accession_number":"0001779128-24-000095","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Air Mobility Q2 net loss narrows to $11.3M; first public Q2 with positive Adj. EBITDA $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M improved $0.9M YoY; revenue $67.9M up 11.4% YoY.","Adjusted EBITDA positive $1.0M vs. -$4.4M prior year; first positive Q2 as public company.","Medical segment revenue record $38.3M (6.4% sequential growth); Medical Adj. EBITDA record $5.5M (+82.7% YoY).","Passenger segment posted first positive Q2 Adjusted EBITDA of $0.8M, improving $2.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":119459000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229227,"accession_number":"0001779128-24-000064","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Blade Air Mobility stockholders elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Susan Lyne elected as Class III director with 28,648,946 for, 8,168,466 withheld; Robert Wiesenthal with 30,585,817 for, 6,231,595 withheld.","Deloitte & Touche ratified as auditor for FY2024: 46,219,104 for, 884,152 against, 18,752 abstain.","Broker non-votes: 10,304,596 on director election; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229226,"accession_number":"0001779128-24-000062","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Q1 net loss narrows to $4.2M; Medical revenue record $36M, up 34.6% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 revenue of $51.5M, up 13.8% YoY; Medical segment revenue hit a record $36.0M.","Net loss improved to ($4.2M) from ($10.2M) a year ago; Adjusted EBITDA loss narrowed to ($3.5M).","Medical Segment Adjusted EBITDA reached $4.4M (+134.5%); Passenger EBITDA loss improved to ($2.7M).","Company reaffirms FY 2024 Adjusted EBITDA profitability and double-digit millions target for 2025.","Gross profit margin expanded to 11.4% from 7.1%, driven by higher-margin Medical revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":51514000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247816,"accession_number":"0001779128-24-000047","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Blade Air Mobility dismisses Marcum, appoints Deloitte as auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Marcum LLP on March 19, 2024; no disagreements on accounting or auditing matters.","Marcum's audit reports for FY2023 were unqualified; material weakness in internal controls was previously disclosed.","Deloitte & Touche LLP appointed on March 20, 2024 as independent auditor for fiscal year ending Dec 31, 2024.","Marcum provided a letter (Exhibit 16.1) agreeing with the Company's statements in this report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247815,"accession_number":"0001779128-24-000040","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Blade Air Mobility announces up to $20M share repurchase program; expects FY2024 adj. EBITDA profit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $20M of Class A common stock; program effective through March 31, 2025.","Repurchases to be funded from cash on hand and cash from operations; program may be suspended or discontinued at any time.","Company expects full-year 2024 profitability on an adjusted EBITDA basis, with debt-free balance sheet and significant cash.","Volume and timing of repurchases subject to market conditions, acquisition opportunities, and capital allocation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247814,"accession_number":"0001779128-24-000012","cik":1779128,"company_name":"Strata Critical Medical, Inc.","ticker":"SRTA","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Blade Q4 revenue up 24.5% to $47.5M; guides for 2024 Adj. EBITDA profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $47.5M (+24.5% YoY); full year revenue $225.2M (+54.1%).","Net loss widened to $(33.9)M in Q4 from $(15.4)M; Adj. EBITDA improved to $(5.2)M from $(8.0)M.","Full year 2023 Adj. EBITDA $(16.6)M; guides for 2024 Adj. EBITDA profitability and 2025 double-digit millions.","Announced pending purchase of eight jet aircraft to support Medical growth; new organ placement service launched.","Medical segment Adj. EBITDA positive $2.5M in Q4, up 57.8% YoY; Passenger Adj. EBITDA loss improved to $(2.6)M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541656336.5602605,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}